Phathom Pharmaceuticals (PHAT) Enterprise Value (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Enterprise Value of -$183.8 million for Q1 2026, up 14.6% year-over-year from -$160.4 million in Q1 2025, and down 41.39% quarter-over-quarter from -$130.0 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Enterprise Value (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Enterprise Value data on file, last reported at -$183.8 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$183.8 million, up 14.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$183.8 million (up 14.6% YoY), and the FY2025 annual result was -$130.0 million, up 56.69% from the prior year.
- Enterprise Value slipped to -$183.8 million in Q1 2026 per PHAT's latest filing, from -$130.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$130.0 million in Q4 2025 and troughed at -$384.3 million in Q4 2023.
- A 5-year average of -$220.1 million and a median of -$207.9 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value slumped 149.92% in 2024, then soared 59.11% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$155.9 million in 2022, then sank by 146.49% to -$384.3 million in 2023, then climbed by 21.89% to -$300.1 million in 2024, then jumped by 56.69% to -$130.0 million in 2025, then plunged by 41.39% to -$183.8 million in 2026.
- Business Quant data shows PHAT's Enterprise Value at -$183.8 million in Q1 2026, -$130.0 million in Q4 2025, and -$138.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -183.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.77 Mn |
| Dec 31, 2025 | -129.97 Mn |
| Sep 30, 2025 | -138.02 Mn |
| Jun 30, 2025 | -152.43 Mn |
| Mar 31, 2025 | -215.18 Mn |
| Dec 31, 2024 | -300.13 Mn |
| Sep 30, 2024 | -337.54 Mn |
| Jun 30, 2024 | -279.10 Mn |
| Mar 31, 2024 | -325.10 Mn |
| Dec 31, 2023 | -384.26 Mn |
| Sep 30, 2023 | -216.54 Mn |
| Jun 30, 2023 | -249.38 Mn |
| Mar 31, 2023 | -130.08 Mn |
| Dec 31, 2022 | -155.89 Mn |
| Sep 30, 2022 | -197.34 Mn |
| Jun 30, 2022 | -207.90 Mn |
| Mar 31, 2022 | -138.60 Mn |
| Dec 31, 2021 | -183.42 Mn |
| Sep 30, 2021 | -224.62 Mn |
| Jun 30, 2021 | -209.67 Mn |